Thompson Siegel & Walmsley LLC grew its holdings in BioTelemetry, Inc. (NASDAQ:BEAT) by 24.3% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 538,107 shares of the medical research company’s stock after acquiring an additional 105,345 shares during the quarter. Thompson Siegel & Walmsley LLC owned about 1.66% of BioTelemetry worth $17,758,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Winslow Evans & Crocker Inc. purchased a new position in BioTelemetry during the 3rd quarter worth approximately $109,000. Pinebridge Investments L.P. grew its stake in BioTelemetry by 2.0% during the 2nd quarter. Pinebridge Investments L.P. now owns 3,775 shares of the medical research company’s stock worth $126,000 after buying an additional 75 shares during the last quarter. Victory Capital Management Inc. grew its stake in BioTelemetry by 17.6% during the 2nd quarter. Victory Capital Management Inc. now owns 4,177 shares of the medical research company’s stock worth $140,000 after buying an additional 626 shares during the last quarter. US Bancorp DE purchased a new position in BioTelemetry during the 2nd quarter worth approximately $145,000. Finally, State of Alaska Department of Revenue grew its stake in BioTelemetry by 80.1% during the 2nd quarter. State of Alaska Department of Revenue now owns 5,638 shares of the medical research company’s stock worth $188,000 after buying an additional 2,508 shares during the last quarter. Institutional investors and hedge funds own 82.23% of the company’s stock.
Shares of BioTelemetry, Inc. (NASDAQ:BEAT) traded up $1.25 during mid-day trading on Thursday, reaching $28.05. The company had a trading volume of 411,273 shares, compared to its average volume of 480,775. The firm has a market capitalization of $850.71, a PE ratio of 35.96, a PEG ratio of 1.64 and a beta of 0.53. BioTelemetry, Inc. has a 52-week low of $20.35 and a 52-week high of $39.20. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.48 and a current ratio of 1.60.
BioTelemetry (NASDAQ:BEAT) last issued its quarterly earnings data on Tuesday, November 7th. The medical research company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.09). The firm had revenue of $81.02 million for the quarter, compared to analyst estimates of $82.10 million. BioTelemetry had a return on equity of 13.66% and a net margin of 16.10%. The business’s revenue for the quarter was up 52.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.21 earnings per share. sell-side analysts anticipate that BioTelemetry, Inc. will post 0.83 EPS for the current year.
BEAT has been the subject of a number of recent research reports. Dougherty & Co increased their price objective on BioTelemetry from $37.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Sidoti reaffirmed a “buy” rating and set a $49.00 price objective (up from $42.00) on shares of BioTelemetry in a research report on Thursday, August 10th. Zacks Investment Research raised BioTelemetry from a “hold” rating to a “strong-buy” rating and set a $39.00 price objective for the company in a research report on Friday, August 11th. BidaskClub raised BioTelemetry from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 16th. Finally, Off Wall Street began coverage on BioTelemetry in a report on Friday, September 15th. They issued a “sell” rating for the company. Two analysts have rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $42.86.
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with MarketBeat.com's FREE daily email newsletter.